Glucagon Route of Administration: A Complete Guide
Abstract: This comprehensive guide analyzes glucagon administration routes (intramuscular, subcutaneous, intranasal) within the peptide product landscape. Market trends show a 12.4% CAGR (2024–2030) driven by diabetes and obesity therapies. Brand comparisons (e.g., Eli Lilly vs. Novo Nordisk) highlight efficacy vs. stability trade-offs. Technical parameters include bioavailability (IM: 85%, IN: 70%) and onset time. Peptide product certifications (GMP, FDA) are critical for quality assurance. Selection criteria emphasize purity (>98%), cold-chain logistics (2–8°C), and manufacturer GMP compliance. Industry data indicates 34% of peptide failures stem from improper storage. This guide integrates product specifications, brand benchmarks, and regulatory insights for informed procurement.